Madjid Momeni-Moghaddam
Abstract
Many genetic, epigenetic, and cellular studies on cancer are underway today, and the completion of the genetic and epigenetic library of cancer could be the way to treat the disease in the future. In this study, we have investigated the parallel gene expression changes of EZH2 and miR-155. So far no ...
Read More
Many genetic, epigenetic, and cellular studies on cancer are underway today, and the completion of the genetic and epigenetic library of cancer could be the way to treat the disease in the future. In this study, we have investigated the parallel gene expression changes of EZH2 and miR-155. So far no study has examined the role of these two factors simultaneously and the results of this study could be useful for further studies. For this purpose, using specific shRNA, the EZH2 gene of HCT116 cells was downregulated and then the changes in expression of the miR-155 were investigated. For gene expression study, Real-time PCR as a standard quantitative method was used. The findings of this study showed that in HCT116 human colon cancer cells, downregulation of miR-155 using shRNA can reduce EZH2 expression and also can promote a significant increase in the expression of TP53INP1 gene. Based on the results, we can emphasize the interaction between these two genes. Importantly, EZH2 downregulation has been able to decrease the amount of miR-155 that has also increased expression in many types of cancers. It may be of interest in epigenetic treatments of colon cancer, because miR-155 can control a very important tumor suppressor gene, TP53INP1.
